SecBot SecBot
SECBOTREPLAY Home › Report › AZN

AZN · AstraZeneca announced positive high-level results from the Phase III…

ASTRAZENECA PLC · 6-K filed Apr 20, 2026 at 07:03 ET

At the news

BULLISHIMPACT 7/10

6-K filed Apr 20, 2026 at 07:03 ET

AstraZeneca announced positive high-level results from the Phase III MIRANDA trial, showing that tozorakimab significantly reduced moderate-to-severe COPD exacerbations. This marks the third successful pivotal trial for the drug, reinforcing its potential as a first-in-class IL-33-targeting biologic.

  • Tozorakimab met the primary endpoint in the Phase III MIRANDA trial, demonstrating a statistically significant and clinically meaningful reduction in the annualized rate of moderate-to-severe COPD exacerbations.
  • This is the third positive pivotal Phase III trial for tozorakimab, following prior successes in the OBERON and TITANIA trials.
  • The MIRANDA trial evaluated a biweekly dosing regimen, expanding on previous monthly dosing data.
  • Tozorakimab was generally well tolerated with a safety profile consistent with prior trials.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access